1977030D.AX

Novotech at ESMO Congress 2022 - New Data Shows 100% Oncology Trials Growth in APAC

Retrieved on: 
Monday, September 5, 2022
Technology, Cancer, Lists of people executed in the United States, Ownership, Incidence, ESMO, Investment, GlobalData, Leadership, Cros, Clinical trial, Growth, Drug development, CRO, Fine chemical, Asia-Pacific

Novotech has experienced CRO operations across APAC and the US offering a unique and unparalleled suite of services for early to late phase biotech clinical research.

Key Points: 
  • Novotech has experienced CRO operations across APAC and the US offering a unique and unparalleled suite of services for early to late phase biotech clinical research.
  • In the APAC region, the proportion of oncology trials doubled during 2017-2021.
  • In China, the growth in oncology trials was associated with a significant increase in cancer incidence, development of innovative products by domestic companies, focus on immune-oncology, and leadership in cell therapy."
  • Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases.

APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report

Retrieved on: 
Friday, September 2, 2022
Technology, NHC, Lists of people executed in the United States, Government, Ownership, Infection, National Medical Products Administration, Degenerative disease, Asia-Pacific, Investment, NMPA, GlobalData, Cros, Plasma protein binding, Clinical trial, National Health Commission, Growth, Drug development, CNS, CRO, Fine chemical, Pharmaceutical industry

The report was prepared by GlobalData and confirms that "the Asia-Pacific (APAC) region was the largest contributor to the global clinical trial landscape from 2017 to 2021, accounting for more than 50% of conducted trials during the analysis period."

Key Points: 
  • The report was prepared by GlobalData and confirms that "the Asia-Pacific (APAC) region was the largest contributor to the global clinical trial landscape from 2017 to 2021, accounting for more than 50% of conducted trials during the analysis period."
  • In addition, the GlobalData research found that all phases of clinical trials in the region registered higher growth than both the US and the EU5.
  • According to Yooni Kim, Vice President, Global Clinical Services Novotech: "Asia-Pacific offers a compelling solution for expedited clinical trials with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition, regulatory reforms have accelerated approval processes.
  • It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas.

Novotech's Flexible Work Policy is Finalist in Best Workplace Flexibility Program "Excellence Award 2022"

Retrieved on: 
Monday, July 25, 2022
People, Flexplace, Culture, Friends, Asia-Pacific, CRO, Information technology, Solution, Travel, Clinical trial, Drug development, Technology, Acceleration, Lists of people executed in the United States, 100 Best Workplaces in Europe, Fine chemical, Pharmaceutical industry, Flex

We are extremely pleased our workplace flexibility efforts are recognised by the Best Workplace Flexibility Program which has selected Novotech as an Excellence Awardee in 2022."

Key Points: 
  • We are extremely pleased our workplace flexibility efforts are recognised by the Best Workplace Flexibility Program which has selected Novotech as an Excellence Awardee in 2022."
  • This renewed way of working incorporates flexible, remote, and in-office working options and aims to create a dynamic business environment and trusted culture.
  • Team members can determine and apply the most effective way to work, unlocking the maximum value of their talent to benefit all stakeholders."
  • Some of the new flexible working policies include:
    - FlexLocation: Work from home, office or other suitable location.